Most Read Articles
30 Nov 2018
New drug applications approved by US FDA as of 16 - 30 November 2018 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Roshini Claire Anthony, 4 days ago

A combination of tocilizumab and methotrexate reduced disease activity at 2 years compared with methotrexate plus prednisone in patients with early rheumatoid arthritis (RA), an effect not demonstrated with tocilizumab monotherapy.

Roshini Claire Anthony, 2 days ago

The use of intramuscular depot medroxyprogesterone acetate (DMPA-IM) did not increase a woman’s risk of acquiring HIV compared with the use of a copper intrauterine device (IUD) or a levonorgestrel implant, results of a study conducted by the ECHO* Trial Consortium show.

14 May 2019
At the recent GLYCEMIC GUARDIANS™ dinner symposium, three eminent speakers spoke on theindispensable role of medical nutrition therapy (MNT) in improving outcomes for patients with type2 diabetes (T2D).

Periprocedural bridging in VTE patients tied to greater bleeding incidence

10 Jul 2019

Compared with vitamin K antagonist (VKA) without bridging, periprocedural bridging is associated with a higher risk of bleeding, with no significant difference in periprocedural venous thromboembolism (VTE) rates, results of a systematic review have shown.

This study sought to examine recurrent VTE and bleeding outcomes with and without bridging in patients with previous VTE due to the uncertain benefits and risks of periprocedural bridging in this population.

The investigators searched the PubMed and Embase databases from inception to 7 December 2017 for randomized and nonrandomized studies that included adults with previous VTE requiring VKA interruption to undergo an elective procedure and that reported VTE or bleeding outcomes. Quality of evidence was graded by consensus.

Twenty-eight cohort studies (20 single-arm cohorts) with a total of 6,915 procedures were analysed. In 27 studies reporting perioperative VTE outcomes, recurrent VTE with bridging had a pooled incidence of 0.7 percent (95 percent CI, 0.4–1.2 percent), while that in recurrent VTE without bridging was 0.5 percent (0.3–0.8 percent).

In 18 studies, major or nonmajor bleeding outcomes were reported. The corresponding pooled incidence of any bleeding for with and without bridging was 3.9 percent (2.0–7.4 percent) and 0.4 percent (0.1–1.7 percent). The pooled incidence for VTE in bridged patients at high thromboembolic risk was 0.8 percent (0.3–2.5 percent) and 7.5 percent (3.1–17.4 percent) for any bleeding.

Due to a high risk of bias among included studies, the quality of available evidence was very low.

“VKA are the most widely used anticoagulants, and bridging is commonly administered during periprocedural VKA interruption,” the investigators said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
30 Nov 2018
New drug applications approved by US FDA as of 16 - 30 November 2018 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Roshini Claire Anthony, 4 days ago

A combination of tocilizumab and methotrexate reduced disease activity at 2 years compared with methotrexate plus prednisone in patients with early rheumatoid arthritis (RA), an effect not demonstrated with tocilizumab monotherapy.

Roshini Claire Anthony, 2 days ago

The use of intramuscular depot medroxyprogesterone acetate (DMPA-IM) did not increase a woman’s risk of acquiring HIV compared with the use of a copper intrauterine device (IUD) or a levonorgestrel implant, results of a study conducted by the ECHO* Trial Consortium show.

14 May 2019
At the recent GLYCEMIC GUARDIANS™ dinner symposium, three eminent speakers spoke on theindispensable role of medical nutrition therapy (MNT) in improving outcomes for patients with type2 diabetes (T2D).